Aakash Desai
@adesaimd.bsky.social
Thoracic/Phase 1 Oncologist @ONealCancerUAB, Asst Prof @UABMedicine | Alum @MayoHemeOnc @UConnIM @MDAndersonNews| Co-Host @HemOncFellows @LungCancerRX
🔍 Does AI reduce #clinician workload?
@NEJM study on @NuanceDragon DAX Copilot, an AI-powered documentation tool, found minimal impact on EHR efficiency & financial metrics❗️
💡AI tools need to be developed in comjuction with 🩺🥼🧑⚕️ not in silos
#AIinMedicine #LLMs @oncoalert.bsky.social
@NEJM study on @NuanceDragon DAX Copilot, an AI-powered documentation tool, found minimal impact on EHR efficiency & financial metrics❗️
💡AI tools need to be developed in comjuction with 🩺🥼🧑⚕️ not in silos
#AIinMedicine #LLMs @oncoalert.bsky.social
December 21, 2024 at 5:17 AM
🔍 Does AI reduce #clinician workload?
@NEJM study on @NuanceDragon DAX Copilot, an AI-powered documentation tool, found minimal impact on EHR efficiency & financial metrics❗️
💡AI tools need to be developed in comjuction with 🩺🥼🧑⚕️ not in silos
#AIinMedicine #LLMs @oncoalert.bsky.social
@NEJM study on @NuanceDragon DAX Copilot, an AI-powered documentation tool, found minimal impact on EHR efficiency & financial metrics❗️
💡AI tools need to be developed in comjuction with 🩺🥼🧑⚕️ not in silos
#AIinMedicine #LLMs @oncoalert.bsky.social
🚨 Breakthrough therapy for ES-SCLC!
@FDA grants sacituzumab govitecan BTD for ES-SCLC progressing on platinum chemo, based on phase II TROPiCS-03 data:
🔹 ORR: 41.9%
🔹 Disease control: 83.7%
🔹 Clinical benefit: 48.8%
Next step: phase III trials. 🤞 this provides another option
#LCSM #SCLC
@FDA grants sacituzumab govitecan BTD for ES-SCLC progressing on platinum chemo, based on phase II TROPiCS-03 data:
🔹 ORR: 41.9%
🔹 Disease control: 83.7%
🔹 Clinical benefit: 48.8%
Next step: phase III trials. 🤞 this provides another option
#LCSM #SCLC
December 18, 2024 at 4:14 AM
Absolutely stunning progress in #lcsm! 🫁
📈 Each month of 2024 has brought incredible advancements—remarkable strides in lung cancer treatment! 💉
✨ Here's another perspective on this impressive journey. Just Ah-mazing! @oncodaily.bsky.social @n8pennell.bsky.social @jackwestmd.bsky.social
📈 Each month of 2024 has brought incredible advancements—remarkable strides in lung cancer treatment! 💉
✨ Here's another perspective on this impressive journey. Just Ah-mazing! @oncodaily.bsky.social @n8pennell.bsky.social @jackwestmd.bsky.social
December 11, 2024 at 5:16 AM
Absolutely stunning progress in #lcsm! 🫁
📈 Each month of 2024 has brought incredible advancements—remarkable strides in lung cancer treatment! 💉
✨ Here's another perspective on this impressive journey. Just Ah-mazing! @oncodaily.bsky.social @n8pennell.bsky.social @jackwestmd.bsky.social
📈 Each month of 2024 has brought incredible advancements—remarkable strides in lung cancer treatment! 💉
✨ Here's another perspective on this impressive journey. Just Ah-mazing! @oncodaily.bsky.social @n8pennell.bsky.social @jackwestmd.bsky.social
Phase I Results AMG 193, PRMT5 inhibitor targeting MTAP-deleted solid tumors: @AnnalsOncology
• 📊 ORR: 21.4% across 8 tumor types (incl. NSCLC, pancreatic & biliary)
• 🛡️ Safety: minimal myelosuppression; nausea & fatigue
• 🎯 MoA: Synthetic lethality in MTAP-deleted cells! @oncoalert.bsky.social
• 📊 ORR: 21.4% across 8 tumor types (incl. NSCLC, pancreatic & biliary)
• 🛡️ Safety: minimal myelosuppression; nausea & fatigue
• 🎯 MoA: Synthetic lethality in MTAP-deleted cells! @oncoalert.bsky.social
December 5, 2024 at 3:36 AM
Phase I Results AMG 193, PRMT5 inhibitor targeting MTAP-deleted solid tumors: @AnnalsOncology
• 📊 ORR: 21.4% across 8 tumor types (incl. NSCLC, pancreatic & biliary)
• 🛡️ Safety: minimal myelosuppression; nausea & fatigue
• 🎯 MoA: Synthetic lethality in MTAP-deleted cells! @oncoalert.bsky.social
• 📊 ORR: 21.4% across 8 tumor types (incl. NSCLC, pancreatic & biliary)
• 🛡️ Safety: minimal myelosuppression; nausea & fatigue
• 🎯 MoA: Synthetic lethality in MTAP-deleted cells! @oncoalert.bsky.social
📢 Breaking news in #SCLC treatment!
Durvalumab is now FDA-approved for limited-stage SCLC based on the ADRIATIC trial. Adding 2 years of durvalumab after chemoradiation improves both PFS and OS (HR 0.73).
This approval marks an important step forward for patients with limited-stage SCLC! 💪
Durvalumab is now FDA-approved for limited-stage SCLC based on the ADRIATIC trial. Adding 2 years of durvalumab after chemoradiation improves both PFS and OS (HR 0.73).
This approval marks an important step forward for patients with limited-stage SCLC! 💪
December 5, 2024 at 12:08 AM
📢 Breaking news in #SCLC treatment!
Durvalumab is now FDA-approved for limited-stage SCLC based on the ADRIATIC trial. Adding 2 years of durvalumab after chemoradiation improves both PFS and OS (HR 0.73).
This approval marks an important step forward for patients with limited-stage SCLC! 💪
Durvalumab is now FDA-approved for limited-stage SCLC based on the ADRIATIC trial. Adding 2 years of durvalumab after chemoradiation improves both PFS and OS (HR 0.73).
This approval marks an important step forward for patients with limited-stage SCLC! 💪
Just an amazing episode! Kudos @drcamidge.bsky.social, so touching! Dr. Camidge puts it so beautifully “Patients are people who happen to be patients and not patients who happen to be people, if you see what I mean.”
Must listen 🎧
Must listen 🎧
December 4, 2024 at 6:49 AM
Just an amazing episode! Kudos @drcamidge.bsky.social, so touching! Dr. Camidge puts it so beautifully “Patients are people who happen to be patients and not patients who happen to be people, if you see what I mean.”
Must listen 🎧
Must listen 🎧
Reposted by Aakash Desai
Interesting…second line lung cancer trial positive (with caveats), now first line pancreatic cancer. Need to see the paper but TTF is here to stay it seems. Positive Topline Results from Phase 3 PANOVA-3Trial of Tumor Treating Fields for Pancreatic Ca.
www.businesswire.com/news/home/20...
www.businesswire.com/news/home/20...
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoi
www.businesswire.com
December 2, 2024 at 11:59 PM
Interesting…second line lung cancer trial positive (with caveats), now first line pancreatic cancer. Need to see the paper but TTF is here to stay it seems. Positive Topline Results from Phase 3 PANOVA-3Trial of Tumor Treating Fields for Pancreatic Ca.
www.businesswire.com/news/home/20...
www.businesswire.com/news/home/20...
Reposted by Aakash Desai
A strategic position statement in @Annals_Oncology on the main actions to boost #lungcancer research and innovation:
✅ Pragmatic trials
✅ Ensure inclusivity and diversity
✅ NGS in resectable #NSCLC
✅ Exploit resistance mech
✅Focus on novel Tox
bit.ly/4ga8LlC
#LCSM #some @iaslc.bsky.social
✅ Pragmatic trials
✅ Ensure inclusivity and diversity
✅ NGS in resectable #NSCLC
✅ Exploit resistance mech
✅Focus on novel Tox
bit.ly/4ga8LlC
#LCSM #some @iaslc.bsky.social
December 1, 2024 at 10:42 PM
A strategic position statement in @Annals_Oncology on the main actions to boost #lungcancer research and innovation:
✅ Pragmatic trials
✅ Ensure inclusivity and diversity
✅ NGS in resectable #NSCLC
✅ Exploit resistance mech
✅Focus on novel Tox
bit.ly/4ga8LlC
#LCSM #some @iaslc.bsky.social
✅ Pragmatic trials
✅ Ensure inclusivity and diversity
✅ NGS in resectable #NSCLC
✅ Exploit resistance mech
✅Focus on novel Tox
bit.ly/4ga8LlC
#LCSM #some @iaslc.bsky.social
Reposted by Aakash Desai
Our latest in @naturecomms.bsky.social from @danafarber.bsky.social / @mskcc.bsky.social collaboration: AI to extract cancer outcomes in EMR!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
November 30, 2024 at 12:54 PM
Our latest in @naturecomms.bsky.social from @danafarber.bsky.social / @mskcc.bsky.social collaboration: AI to extract cancer outcomes in EMR!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Aakash Desai
aacrjournals.org/cancerres/ar...
Study by Herzog and colleagues suggesting cell type–specific epigenetic changes shared by e-cigarette use, smoking, and cancer
#lcsm #lcam @theaacr.bsky.social @fda.gov @iaslc.bsky.social @younglungcancer.bsky.social @lungevity.bsky.social
Study by Herzog and colleagues suggesting cell type–specific epigenetic changes shared by e-cigarette use, smoking, and cancer
#lcsm #lcam @theaacr.bsky.social @fda.gov @iaslc.bsky.social @younglungcancer.bsky.social @lungevity.bsky.social
December 1, 2024 at 9:26 AM
aacrjournals.org/cancerres/ar...
Study by Herzog and colleagues suggesting cell type–specific epigenetic changes shared by e-cigarette use, smoking, and cancer
#lcsm #lcam @theaacr.bsky.social @fda.gov @iaslc.bsky.social @younglungcancer.bsky.social @lungevity.bsky.social
Study by Herzog and colleagues suggesting cell type–specific epigenetic changes shared by e-cigarette use, smoking, and cancer
#lcsm #lcam @theaacr.bsky.social @fda.gov @iaslc.bsky.social @younglungcancer.bsky.social @lungevity.bsky.social
Reposted by Aakash Desai
Pleased to share our paper on the impact of severe irAEs in adv NSCLC #TheOncologist
- 3211pts, ConcertAI database
- 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4%
- s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE
@oncoalert.bsky.social #MedSky #OncSky #LCSM
academic.oup.com/oncolo/advan...
- 3211pts, ConcertAI database
- 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4%
- s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE
@oncoalert.bsky.social #MedSky #OncSky #LCSM
academic.oup.com/oncolo/advan...
Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors
AbstractBackground. Immune checkpoint inhibitors (ICIs) are associated with severe immune-related adverse events (s-irAEs) that result in hospitalization,
academic.oup.com
December 1, 2024 at 12:36 AM
Pleased to share our paper on the impact of severe irAEs in adv NSCLC #TheOncologist
- 3211pts, ConcertAI database
- 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4%
- s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE
@oncoalert.bsky.social #MedSky #OncSky #LCSM
academic.oup.com/oncolo/advan...
- 3211pts, ConcertAI database
- 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4%
- s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE
@oncoalert.bsky.social #MedSky #OncSky #LCSM
academic.oup.com/oncolo/advan...
Reposted by Aakash Desai
⭐️Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither? Nice work spearheaded by @adesaimd.bsky.social
mdpi.com/3031120
mdpi.com/3031120
Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither?
Introduction: Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, despite advances in immune checkpoint inhibitors and targeted therapies. Antibody–drug c...
mdpi.com
November 29, 2024 at 3:16 PM
⭐️Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither? Nice work spearheaded by @adesaimd.bsky.social
mdpi.com/3031120
mdpi.com/3031120
Reposted by Aakash Desai
Ph I trial ABBV-011 (SEZ6-ADC) in SCLC @theaacr.bsky.social
- SEZ6: Seizure-Related Homolog Protein 6 (IHC+ in SCLC)
- 99pts, 67% 2+lines
- TRAEs fatigue 50% nausea 42%
- 1mg/kg dose ORR 25%
- mDOR 4.2m
One to watch in SCLC
@oncoalert.bsky.social #OncSky #LCSM
aacrjournals.org/clincancerre...
- SEZ6: Seizure-Related Homolog Protein 6 (IHC+ in SCLC)
- 99pts, 67% 2+lines
- TRAEs fatigue 50% nausea 42%
- 1mg/kg dose ORR 25%
- mDOR 4.2m
One to watch in SCLC
@oncoalert.bsky.social #OncSky #LCSM
aacrjournals.org/clincancerre...
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
AbstractPurpose:. Seizure-related homolog protein 6 (SEZ6) is a novel target expressed in small cell lung cancer (SCLC). ABBV-011, a SEZ6-targeted antibody conjugated to calicheamicin, was evaluated i...
aacrjournals.org
November 27, 2024 at 7:06 PM
Ph I trial ABBV-011 (SEZ6-ADC) in SCLC @theaacr.bsky.social
- SEZ6: Seizure-Related Homolog Protein 6 (IHC+ in SCLC)
- 99pts, 67% 2+lines
- TRAEs fatigue 50% nausea 42%
- 1mg/kg dose ORR 25%
- mDOR 4.2m
One to watch in SCLC
@oncoalert.bsky.social #OncSky #LCSM
aacrjournals.org/clincancerre...
- SEZ6: Seizure-Related Homolog Protein 6 (IHC+ in SCLC)
- 99pts, 67% 2+lines
- TRAEs fatigue 50% nausea 42%
- 1mg/kg dose ORR 25%
- mDOR 4.2m
One to watch in SCLC
@oncoalert.bsky.social #OncSky #LCSM
aacrjournals.org/clincancerre...
Thrilled to be starting “AI in Health Care: From Strategies to Implementation program” @harvardmed! 🧠💻 Embarking on this to deepen my understanding and applications of AI to revolutionize #medicine and #oncology!
Excited to apply these insights to patient care! 🌟 #AIInMedicine #StudentforLife
Excited to apply these insights to patient care! 🌟 #AIInMedicine #StudentforLife
November 27, 2024 at 2:57 PM
Thrilled to be starting “AI in Health Care: From Strategies to Implementation program” @harvardmed! 🧠💻 Embarking on this to deepen my understanding and applications of AI to revolutionize #medicine and #oncology!
Excited to apply these insights to patient care! 🌟 #AIInMedicine #StudentforLife
Excited to apply these insights to patient care! 🌟 #AIInMedicine #StudentforLife
Reposted by Aakash Desai
Thanks to our amazing patient who brought in delicious White Ribbon cupcakes for the thoracic clinic team to celebrate #LungCancerAwarenessMonth #COH
November 27, 2024 at 4:10 AM
Thanks to our amazing patient who brought in delicious White Ribbon cupcakes for the thoracic clinic team to celebrate #LungCancerAwarenessMonth #COH
Unfortunately, this may mean continually reducing interest in TIGIT as a target!
endpts.com/roches-tigit...
endpts.com/roches-tigit...
Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial
Roche's tiragolumab failed to meet overall survival endpoint in Phase 3 SKYSCRAPER-01 trial when combined with Tecentriq for lung cancer treatment. This follows earlier trial failures in 2023, though ...
endpts.com
November 26, 2024 at 9:27 PM
Unfortunately, this may mean continually reducing interest in TIGIT as a target!
endpts.com/roches-tigit...
endpts.com/roches-tigit...
🧬 “Real-world Dabrafenib-Trametinib (D-T) for BRAF V600E-mutated NSCLC”
The IFCT-2004 BLaDE study confirms:
• Significant efficacy in both pretreated & untreated patients
• 12-month OS: 67.4%
• Median PFS: 10.4 (2L+), 18.2 mths (1L)
🔑 Early BRAF V600E testing is critical for optimizing therapy. 🎯
The IFCT-2004 BLaDE study confirms:
• Significant efficacy in both pretreated & untreated patients
• 12-month OS: 67.4%
• Median PFS: 10.4 (2L+), 18.2 mths (1L)
🔑 Early BRAF V600E testing is critical for optimizing therapy. 🎯
November 26, 2024 at 9:23 PM
🧬 “Real-world Dabrafenib-Trametinib (D-T) for BRAF V600E-mutated NSCLC”
The IFCT-2004 BLaDE study confirms:
• Significant efficacy in both pretreated & untreated patients
• 12-month OS: 67.4%
• Median PFS: 10.4 (2L+), 18.2 mths (1L)
🔑 Early BRAF V600E testing is critical for optimizing therapy. 🎯
The IFCT-2004 BLaDE study confirms:
• Significant efficacy in both pretreated & untreated patients
• 12-month OS: 67.4%
• Median PFS: 10.4 (2L+), 18.2 mths (1L)
🔑 Early BRAF V600E testing is critical for optimizing therapy. 🎯
Reposted by Aakash Desai
Honored to be nominated for ASCO Board of Directors along with 12 other qualified candidates. Only one week remaining to vote and make your voice heard!
society.asco.org/about-asco/a...
society.asco.org/about-asco/a...
November 25, 2024 at 12:05 PM
Honored to be nominated for ASCO Board of Directors along with 12 other qualified candidates. Only one week remaining to vote and make your voice heard!
society.asco.org/about-asco/a...
society.asco.org/about-asco/a...
Reposted by Aakash Desai
Anyone can get lung cancer.
Brandy learned this in 2023. Her diagnosed also clarified what truly matters: time with her guys.
Let's advocate for more research, so more people like Brandy have all the time in the world. @oncogenecancer.bsky.social
#BecauseofResearch #LCSM
Brandy learned this in 2023. Her diagnosed also clarified what truly matters: time with her guys.
Let's advocate for more research, so more people like Brandy have all the time in the world. @oncogenecancer.bsky.social
#BecauseofResearch #LCSM
November 23, 2024 at 5:09 PM
Anyone can get lung cancer.
Brandy learned this in 2023. Her diagnosed also clarified what truly matters: time with her guys.
Let's advocate for more research, so more people like Brandy have all the time in the world. @oncogenecancer.bsky.social
#BecauseofResearch #LCSM
Brandy learned this in 2023. Her diagnosed also clarified what truly matters: time with her guys.
Let's advocate for more research, so more people like Brandy have all the time in the world. @oncogenecancer.bsky.social
#BecauseofResearch #LCSM
Impact of lung biomarker testing on out-of-pocket costs for metastatic non-small cell lung cancer - @ClinicalLung
◾️ Median OOP cost of $98 (IQR: $43.8-$306.5)
◾️Biomarker testing total OOP cost of all services in 6 mths of diagnosis: $3560.2 compared to $1979.6 for those who did not! bit.ly/4hUTqaa
◾️ Median OOP cost of $98 (IQR: $43.8-$306.5)
◾️Biomarker testing total OOP cost of all services in 6 mths of diagnosis: $3560.2 compared to $1979.6 for those who did not! bit.ly/4hUTqaa
November 23, 2024 at 4:07 PM
Impact of lung biomarker testing on out-of-pocket costs for metastatic non-small cell lung cancer - @ClinicalLung
◾️ Median OOP cost of $98 (IQR: $43.8-$306.5)
◾️Biomarker testing total OOP cost of all services in 6 mths of diagnosis: $3560.2 compared to $1979.6 for those who did not! bit.ly/4hUTqaa
◾️ Median OOP cost of $98 (IQR: $43.8-$306.5)
◾️Biomarker testing total OOP cost of all services in 6 mths of diagnosis: $3560.2 compared to $1979.6 for those who did not! bit.ly/4hUTqaa
Reposted by Aakash Desai
#LCSM is Lung Cancer Social Media. Please tag your LC related posts. It’s very helpful.
Might we implement hashtag cancer communities on Bluesky? They genuinely help stakeholders (esp patients) find info related to a specific cancer. This paper explains how #bcsm #btsm #lcsm and other cancer community hashtags evolved on Twitter. ascopubs.org/doi/pdfdirec...
ascopubs.org
November 23, 2024 at 2:00 AM
#LCSM is Lung Cancer Social Media. Please tag your LC related posts. It’s very helpful.
So #oncosky peeps, how are you using your #SoMe time these days?
1. BlueSky Only
2. X and BlueSky
3. X, BlueSky and LinkedIn
4. X, BlueSky, LinkedIn and Instagram/TikTok/Others? (At this point you have my deep respect 🙏)
Also just realized, @bsky.app needs a poll function!!!!
1. BlueSky Only
2. X and BlueSky
3. X, BlueSky and LinkedIn
4. X, BlueSky, LinkedIn and Instagram/TikTok/Others? (At this point you have my deep respect 🙏)
Also just realized, @bsky.app needs a poll function!!!!
November 23, 2024 at 12:35 AM
Reposted by Aakash Desai
Illustration of main ADCs in clinical development for oncogene-addicted #NSCLC. Nice data for both biomarker-agnostic ( anti-TROP2) and biomarker-driven ADCs for various targets and payloads. Drug-to-Ab ratio is depicted by the N of red pins on the Ab surface. @iaslc.bsky.social
#some #lungcancer
#some #lungcancer
November 22, 2024 at 10:29 PM
Illustration of main ADCs in clinical development for oncogene-addicted #NSCLC. Nice data for both biomarker-agnostic ( anti-TROP2) and biomarker-driven ADCs for various targets and payloads. Drug-to-Ab ratio is depicted by the N of red pins on the Ab surface. @iaslc.bsky.social
#some #lungcancer
#some #lungcancer
Reposted by Aakash Desai
Flew from Shanghai to Seattle to Lake Tahoe yday to attend #MaTOS24 conference today, where Claudia Henschke kicks off on screening.
Great to catch up with so many colleagues, many of whom have been prolific on X but may be thinking about transitioning here. Will try to nudge them along.
Great to catch up with so many colleagues, many of whom have been prolific on X but may be thinking about transitioning here. Will try to nudge them along.
November 22, 2024 at 4:19 PM
Flew from Shanghai to Seattle to Lake Tahoe yday to attend #MaTOS24 conference today, where Claudia Henschke kicks off on screening.
Great to catch up with so many colleagues, many of whom have been prolific on X but may be thinking about transitioning here. Will try to nudge them along.
Great to catch up with so many colleagues, many of whom have been prolific on X but may be thinking about transitioning here. Will try to nudge them along.
